TRANSDERMAL NICOTINE FOR SMOKERS WITH SCHIZOPHRENIA

用于患有精神分裂症的吸烟者的透皮尼古丁

• 批准号: 7376046
• 负责人: MICHAEL SMITH
• 金额: $ 4.43万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376046
• 关键词: TRANSDERMAL; NICOTINE; SMOKERS; SCHIZOPHRENIA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is to conduct a randomized, double-blind, placebo controlled study comparing the effectiveness and clinical relevance of two forms of nicotine replacement (high versus low) with placebo. Data derived from this study will be analyzed in regard to a number of clinically and theoretically important questions, including the following: 1. Overall effectiveness of nicotine replacement treatment in this vulnerable group of patients, 2. Relative efficacy of the two types of treatment, 3. Relative efficacy of these treatment methods in patients who are also treated with different types of neuroleptics (atypical vs typicals), 4. Pharmacogenetics factors that might be associated with the success of smoking cessation. 5. The effect of smoking cessation on the expression of the enzymes 1A2 and the steady state of the neuroleptic and 6. The potential effect of smoke cessation on the side effect profiles, dosing and symptoms of patients.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本项目将进行一项随机、双盲、安慰剂对照研究，比较两种尼古丁替代品（高与低）与安慰剂的有效性和临床相关性。从本研究中获得的数据将被分析关于一些临床和理论上重要的问题，包括：1。尼古丁替代治疗在这一弱势患者群体中的总体有效性2 .两种治疗方法的相对疗效；4.这些治疗方法在同时使用不同类型抗精神病药的患者中的相对疗效（非典型与典型）。药物遗传学因素可能与戒烟成功有关。5. 戒烟对1A2酶表达及抗精神病药物稳定状态的影响。戒烟对副作用、剂量和患者症状的潜在影响。